Filtered By:
Cancer: Carcinoma
This page shows you your search results in order of date. This is page number 17.
Order by Relevance | Date
Total 98998 results found since Jan 2013.
Necrotizing pneumonia due to Aspergillus and Salmonella after immune checkpoint inhibitor treatment: An unusual case and review of the literature
CONCLUSIONS: Awareness of unusual pathogens in the etiology of pneumonia after ICI treatment may help to avoid underdiagnosis.PMID:37714729 | DOI:10.1016/j.riam.2023.05.001
Source: Revista Iberoamericana de Micologia - September 15, 2023 Category: Biology Authors: Muhammed Cihan I şık O ğuz Karcıoğlu G ülşen Hazırolan Dolunay G ülmez Mehmet Ruhi Onur Mehmet Mahir Kunt Sevtap Arikan-Akdagli G ökhan Metan Source Type: research
How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ
Surg Oncol Clin N Am. 2023 Oct;32(4):663-673. doi: 10.1016/j.soc.2023.05.011. Epub 2023 Jun 15.ABSTRACTDCIS detection has increased dramatically since the introduction of screening mammography. Current guidance concordant care recommends surgical intervention for all patients with DCIS, followed by radiation and/or endocrine therapy for some. Adjuvant therapies after surgical excision have reduced recurrence rates but not breast cancer mortality. Given the lack of evidence of current treatment regimens and the morbidity associated with these treatments, there is concern that DCIS is over-treated. Active surveillance may be...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Sydney M Record Eun-Sil Shelley Hwang Akiko Chiba Source Type: research
Nasopharyngeal carcinoma patient-derived xenograft mouse models reveal potential drugs targeting cell cycle, mTOR, and autophagy pathways
CONCLUSIONS: High mTOR levels are a poor prognostic factor in NPC, and cell cycle, mTOR and autophagy pathways may serve as therapeutic targets in NPC. In addition, PDX models can be used for efficiently testing potential NPC drugs.PMID:37713975 | DOI:10.1016/j.tranon.2023.101785
Source: Translational Oncology - September 15, 2023 Category: Cancer & Oncology Authors: Hsin-Pai Li Chen-Yang Huang Kar-Wai Lui Yin-Kai Chao Chun-Nan Yeh Li-Yu Lee Yenlin Huang Tung-Liang Lin Yung-Chia Kuo Mei-Yuan Huang Hsien-Chi Fan An-Chi Lin Chia-Hsun Hsieh Kai-Ping Chang Chien-Yu Lin Hung-Ming Wang Mei Chao Jai-Shin Liu Yu-Sun Chang Che Source Type: research
Podophyllotoxin reduces the aggressiveness of human oral squamous cell carcinoma through myeloid cell leukemia ‑1
Int J Mol Med. 2023 Nov;52(5):103. doi: 10.3892/ijmm.2023.5306. Epub 2023 Sep 15.ABSTRACTPodophyllotoxin (PPT), which is derived from the podophyllum plant, exhibits marked cytotoxic effects against cancer cells; however, the precise molecular mechanism underlying its activity against human oral squamous cell carcinoma (OSCC) has not been elucidated. In the present study, the mechanism by which PPT induced cytotoxicity in two OSCC cell lines, HSC3 and HSC4, was determined. The effects of PPT on cytotoxicity in HSC3 and HSC4 cells were analyzed using Annexin V/PI double staining, Sub‑G1 analysis, soft agar assays, western...
Source: Molecular Medicine - September 15, 2023 Category: Molecular Biology Authors: Hyun-Ju Yu Ji-Ae Shin Su-Jung Choi Sung-Dae Cho Source Type: research
Epiberberine suppresses the metastasis of head and neck squamous cell carcinoma cells by regulating the MMP-13 and JNK pathway
In conclusion, the present study demonstrates that epiberberine suppresses cell migration and invasion by regulating the JNK pathway and MMP-13. These results suggest that epiberberine could be a potential antimetastatic agent in HNSCC cells.PMID:37710409 | DOI:10.1111/jcmm.17954
Source: Molecular Medicine - September 15, 2023 Category: Molecular Biology Authors: Hsin-Yu Ho Mu-Kuan Chen Chia-Chieh Lin Yu-Sheng Lo Yi-Ching Chuang Ming-Ju Hsieh Source Type: research
Oncogenic pathways refine a new perspective on the classification of hepatocellular carcinoma
CONCLUSIONS: ADP provides a new perspective for identifying patients at high risk of recurrence and could optimize precision treatment to improve the clinical outcomes in HCC.PMID:37714446 | DOI:10.1016/j.cellsig.2023.110890
Source: Cellular Signalling - September 15, 2023 Category: Cytology Authors: Yuyuan Zhang Zaoqu Liu Jie Li Bailu Wu Xin Li Mengjie Duo Hui Xu Long Liu Xiaoxing Su Xuhua Duan Peng Luo Jian Zhang Zhen Li Source Type: research
Resection of Papillary Thyroid Carcinoma Involving a Functioning Recurrent Laryngeal Nerve: Pushing Boundaries to Preserve Nerve Function
Ann Surg Oncol. 2023 Sep 15. doi: 10.1245/s10434-023-14287-5. Online ahead of print.NO ABSTRACTPMID:37713120 | DOI:10.1245/s10434-023-14287-5
Source: Ann Oncol - September 15, 2023 Category: Cancer & Oncology Authors: Anthony T Saxton Randall P Scheri Source Type: research
How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ
Surg Oncol Clin N Am. 2023 Oct;32(4):663-673. doi: 10.1016/j.soc.2023.05.011. Epub 2023 Jun 15.ABSTRACTDCIS detection has increased dramatically since the introduction of screening mammography. Current guidance concordant care recommends surgical intervention for all patients with DCIS, followed by radiation and/or endocrine therapy for some. Adjuvant therapies after surgical excision have reduced recurrence rates but not breast cancer mortality. Given the lack of evidence of current treatment regimens and the morbidity associated with these treatments, there is concern that DCIS is over-treated. Active surveillance may be...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Sydney M Record Eun-Sil Shelley Hwang Akiko Chiba Source Type: research
Podophyllotoxin reduces the aggressiveness of human oral squamous cell carcinoma through myeloid cell leukemia ‑1
Int J Mol Med. 2023 Nov;52(5):103. doi: 10.3892/ijmm.2023.5306. Epub 2023 Sep 15.ABSTRACTPodophyllotoxin (PPT), which is derived from the podophyllum plant, exhibits marked cytotoxic effects against cancer cells; however, the precise molecular mechanism underlying its activity against human oral squamous cell carcinoma (OSCC) has not been elucidated. In the present study, the mechanism by which PPT induced cytotoxicity in two OSCC cell lines, HSC3 and HSC4, was determined. The effects of PPT on cytotoxicity in HSC3 and HSC4 cells were analyzed using Annexin V/PI double staining, Sub‑G1 analysis, soft agar assays, western...
Source: International Journal of Molecular Medicine - September 15, 2023 Category: Molecular Biology Authors: Hyun-Ju Yu Ji-Ae Shin Su-Jung Choi Sung-Dae Cho Source Type: research
Necrotizing pneumonia due to Aspergillus and Salmonella after immune checkpoint inhibitor treatment: An unusual case and review of the literature
CONCLUSIONS: Awareness of unusual pathogens in the etiology of pneumonia after ICI treatment may help to avoid underdiagnosis.PMID:37714729 | DOI:10.1016/j.riam.2023.05.001
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Muhammed Cihan I şık O ğuz Karcıoğlu G ülşen Hazırolan Dolunay G ülmez Mehmet Ruhi Onur Mehmet Mahir Kunt Sevtap Arikan-Akdagli G ökhan Metan Source Type: research
Epiberberine suppresses the metastasis of head and neck squamous cell carcinoma cells by regulating the MMP-13 and JNK pathway
In conclusion, the present study demonstrates that epiberberine suppresses cell migration and invasion by regulating the JNK pathway and MMP-13. These results suggest that epiberberine could be a potential antimetastatic agent in HNSCC cells.PMID:37710409 | DOI:10.1111/jcmm.17954
Source: J Cell Mol Med - September 15, 2023 Category: Molecular Biology Authors: Hsin-Yu Ho Mu-Kuan Chen Chia-Chieh Lin Yu-Sheng Lo Yi-Ching Chuang Ming-Ju Hsieh Source Type: research
Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma
CONCLUSION: Thyroid dysfunction is a common immune-related adverse events in advanced cancer patients treated with anti-PD-1 therapy and predicts a better prognosis.TRIAL REGISTRATION: This study was retrospectively registered with Trial ClinicalTrials.gov (NCT05593744) on October 25, 2022.PMID:37715029 | DOI:10.1007/s00432-023-05364-z
Source: Cell Research - September 15, 2023 Category: Cytology Authors: Yiran Lu Qingchen Li Lusi Xu Yanqing Zheng Yanchao Wang Ying Liu Rui Zhang Lin Liao Jianjun Dong Source Type: research
Resveratrol Inhibits Hepatocellular Carcinoma Progression Through Regulating Exosome Secretion
CONCLUSION: Resveratrol inhibits hepatocellular carcinoma progression by regulating exosome secretion and contents.PMID:37711128 | DOI:10.2174/0929867331666230914090053
Source: Current Medicinal Chemistry - September 15, 2023 Category: Chemistry Authors: Kun Tong Pingfeng Wang Ying Li Yaoyao Tong Xuejie Li Shirong Yan Pei Hu Source Type: research
Two-dimensional chromatography for enantiomeric analysis of mitotane and its metabolite o,p'-DDA in patients with adrenocortical carcinoma indicates enantioselective metabolism
In this study, we analyzed the enantiomers of mitotane and o,p'-DDA in the plasma of patients by a newly developed chiral-phase method employed in two-dimensional chromatography. Important differences were observed in the ratio of (S)/(R)-mitotane, which varied substantially from 1:1.2 to 1:10 whereas the (S)/(R)-o,p'-DDA ratio was relatively conserved, at approximately 2:1. These findings provide evidence for the enantioselective metabolism and provide a method for further analyses of mitotane and metabolites, which can explain the variation in the therapeutic response.PMID:37713949 | DOI:10.1016/j.bioorg.2023.106835
Source: Bioorganic Chemistry - September 15, 2023 Category: Chemistry Authors: Gabriela Stadler Alan de Almeida Veiga Claudia Rita Corso Camila Bach de Assis Beatriz de Toledo Nogueira Lucia Regina Rocha Martins Beatriz Cruz Bonk Fl ávia Lada Degaut Pontes Bonald Cavalcante de Figueiredo Lauro Mera de Souza Source Type: research
DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma
Cancer Res. 2023 Sep 15. doi: 10.1158/0008-5472.CAN-22-4001. Online ahead of print.ABSTRACTThe KEAP1-NRF2 axis is the principal regulator of cellular responses to oxidative and electrophilic stressors. NRF2 hyperactivation is frequently observed in many types of cancer and promotes cancer initiation, progression, metastasis, and resistance to various therapies. Here, we determined that dipeptidyl peptidase 9 (DPP9) is a regulator of the KEAP1-NRF2 pathway in clear cell renal cell carcinoma (ccRCC). DPP9 was markedly overexpressed at the mRNA and protein levels in ccRCC, and high DPP9 expression levels correlated with advan...
Source: Cell Research - September 15, 2023 Category: Cytology Authors: Kun Chang Yingji Chen Xuanzhi Zhang Wei Zhang Ning Xu Bohan Zeng Yue Wang Tao Feng Bo Dai Fujiang Xu Dingwei Ye Chenji Wang Source Type: research
